DRREDDY

Dr. Reddy's Laboratories Share Price

₹1,272.20 +3.9 (0.31%)

05 Nov, 2024 19:22

SIP TrendupStart SIP in DRREDDY

Start SIP

Performance

  • Low
  • ₹1,241
  • High
  • ₹1,279
  • 52 Week Low
  • ₹1,057
  • 52 Week High
  • ₹1,421
  • Open Price₹1,265
  • Previous Close₹1,268
  • Volume1,603,920

Investment Returns

  • Over 1 Month -4.1%
  • Over 3 Month -8.66%
  • Over 6 Month + 0.18%
  • Over 1 Year + 20.86%
SIP Lightning

Smart Investing Starts Here Start SIP with Dr. Reddy's Laboratories for Steady Growth!

Dr. Reddy's Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 19.1
  • PEG Ratio
  • 1.1
  • Market Cap Cr
  • 106,150
  • P/B Ratio
  • 3.8
  • Average True Range
  • 32.3
  • EPS
  • 51.3
  • Dividend Yield
  • 0.6
  • MACD Signal
  • -13.69
  • RSI
  • 38.56
  • MFI
  • 36.24

Dr. Reddy's Laboratories Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations5,841.205,081.804,103.004,838.705,437.30
Total Income From Operations5,841.205,104.804,103.004,838.705,437.30
P/L Before Interest, Excpt. Items & Tax1,921.001,345.10637.501,606.402,224.10
P/L Before Exceptional Items & Tax1,913.901,339.20631.901,600.602,219.60
P/L After Tax from Ordinary Activities1,417.201,034.80475.201,192.601,639.40
Net Profit/Loss For the Period1,417.201,034.80475.201,192.601,639.40
IndicatorMar 24Mar 23
Revenue From Operations [Gross]19,404.1016,899.10
Revenue From Operations [Net]19,404.1016,899.10
Total Operating Revenues19,483.8016,962.50
Total Revenue20,346.1017,553.80
Total Expenses14,554.8013,687.80
Profit/Loss Before Tax5,791.303,866.00
Profit/Loss For The Period4,342.002,612.80
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity3,449.705,052.90
Net Cash Used In Investing Activity-3,430.30-3,447.60
Net Cash Used in Finance Activity68.10-2,696.90
Net Inc/Dec In Cash And Equivalent89.10-1,047.10
Cash And Equivalent End Of Year201.40112.30
IndicatorMar 24Mar 23
Total Share Capital83.4083.30
Total Non-Current Liabilities580.40460.90
Total Current Liabilities5,538.104,439.70
Total Capital And Liabilities30,359.3025,374.80
Total Non-Current Assets12,543.4011,586.50
Total Current Assets17,815.9013,788.30
Total Assets30,359.3025,374.80
Indicator20242023
EBIT Margin (%)29.8322.89
Return On Capital Employed (%)23.4118.54
Return On Equity (%)17.9112.76
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)290.66245.79
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations7,696.107,083.007,236.806,902.606,757.90
Total Income From Operations7,696.107,113.807,236.806,902.606,757.90
P/L Before Interest, Excpt. Items & Tax1,936.501,661.001,865.801,947.801,882.80
P/L Before Exceptional Items & Tax1,876.701,601.701,826.401,912.501,845.70
P/L After Tax from Ordinary Activities1,386.501,306.301,378.201,478.001,400.70
Net Profit/Loss For the Period1,386.501,306.301,378.201,478.001,400.70
IndicatorMar 24Mar 23
Revenue From Operations [Gross]27,916.4024,587.90
Revenue From Operations [Net]27,916.4024,587.90
Total Operating Revenues28,011.1024,669.70
Total Revenue28,905.4025,725.20
Total Expenses21,719.1019,713.70
Profit/Loss Before Tax7,186.306,011.50
Profit/Loss For The Period5,563.204,470.30
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity4,543.305,887.50
Net Cash Used In Investing Activity-4,028.30-4,137.30
Net Cash Used in Finance Activity-376.30-2,686.10
Net Inc/Dec In Cash And Equivalent132.80-907.30
Cash And Equivalent End Of Year710.70577.90
IndicatorMar 24Mar 23
Total Share Capital83.4083.30
Total Non-Current Liabilities1,021.00426.90
Total Current Liabilities9,588.008,572.10
Total Capital And Liabilities38,863.8032,285.10
Total Non-Current Assets14,058.5011,859.60
Total Current Assets24,805.3020,425.50
Total Assets38,863.8032,285.10
Indicator20242023
EBIT Margin (%)26.2624.94
Return On Capital Employed (%)25.1325.95
Return On Equity (%)19.7419.35
Long Term Debt To Equity (%)1.340.00
Book Value/Share (INR)338.79279.55

Dr. Reddy's Laboratories Technicals

EMA & SMA

Current Price
₹1,272.20
+ 3.9 (0.31%)
pointer
  • stock-down_img
  • Bullish Moving Average 3
  • stock-up_img
  • Bearish Moving Average 13
  • 20 Day
  • ₹1,300.42
  • 50 Day
  • ₹1,318.71
  • 100 Day
  • ₹1,310.08
  • 200 Day
  • ₹1,266.92

Resistance and Support

1264.15 Pivot Speed
  • R3 1,324.80
  • R2 1,301.90
  • R1 1,287.05
  • S1 1,249.30
  • S2 1,226.40
  • S3 1,211.55

Is Dr. Reddy's Laboratories Worth Buying?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Dr. Reddy's Laboratories Ltd. is a global pharmaceutical company based in India, offering a wide range of generic medicines, biosimilars, and specialty pharmaceuticals. The company serves patients in over 150 countries with high-quality, affordable healthcare solutions. Dr. Reddy's Laboratories has an operating revenue of Rs. 28,949.30 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 26% is great, ROE of 19% is exceptional. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 88 which is a GOOD score indicating consistency in earnings, a RS Rating of 36 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Dr. Reddy's Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-05 Quarterly Results
2024-07-27 Quarterly Results & Stock Split
2024-05-07 Audited Results & Final Dividend
2024-01-30 Quarterly Results
2023-10-27 Quarterly Results
Date Purpose Remarks
2024-10-28 Split Rs.0.00 Split from Rs. 5/- to Re. 1/-

Dr. Reddy's Laboratories F&O

Dr. Reddy's Laboratories Shareholding Pattern

26.64%
10.86%
7.7%
27.53%
0.16%
8.07%
19.04%

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a worldwide pharmaceutical corporation headquartered in Hyderabad, Telangana, India. Kallam Anji Reddy, who had worked at the mentor institute Indian Drugs and Pharmaceuticals Limited, started the company. A vast variety of pharmaceuticals are produced and sold by Dr. Reddy in India and other countries. They produce about 190 medications, and 60 active pharmaceutical ingredients (APIs) for the production of pharmaceuticals, diagnostic tools, critical care products, and biotechnology products, among other things.

“It was a dream. It was not a plan on the drawing board, no. But it was a dream.”

- DR. K ANJI REDDY

With one medicine in a 60-tonne facility close to Hyderabad, Dr. Reddy's launched its business in the Active Pharmaceutical Ingredients (API) category in 1984. It sent its first shipment of Methyldopa medication to West Germany in 1986. It is one of the top three API providers worldwide. They also entered the international market this year with the introduction of the API Methyldopa. In 1987, they received their first USFDA approval for the API Ibuprofen. They have been manufacturing omeprazole, one of the most well-known products, since 1991. They entered Russia, which at the time was the biggest international market, in 1992. To direct research into new cancer and diabetes medicines, the Dr. Reddy's Research Foundation was founded in 1993.

To address the needs of children, teenagers, and women who are at risk in both the economic and social spheres,In 1996, Dr. Reddy's Foundation was founded. They began their biologics business in 1998 with the goal of providing inexpensive access to expensive pharmaceuticals to Indian patients.

As part of their continued global expansion, they bought BMS Laboratories Limited and Meridian Healthcare in the UK in 2002 and released a drug for advanced prostate cancer in India, becoming the first company to introduce Bicalutamide in India. The corporation established Dr. Reddy's Foundation for Health Education and a breast cancer helpline in Mumbai.

In the US, ibuprofen was first made accessible as a generic medication in 2003.

To treat autoimmune diseases and tumors, including non-lymphoma, Hodgkin's introduced the first monoclonal antibody biosimilar in history in 2007. In 2009, revenue in Russia and the CIS exceeded $150 million. In 2012, revenue exceeded USD 2 billion.

By 2016 the business entered the market for branded consumer health goods by purchasing six OTC brands from Ducere Pharma The company just announced its entry into Colombia with a variety of excellent, cost-effective medications for cancer patients.

By purchasing six over-the-counter (OTC) brands from Ducere Pharma in 2016, the company entered the market for branded consumer health products. The business announced its arrival in Colombia with a selection of top-notch, reasonably priced drugs for people with cancer.

In 2017 they expanded their commercial operations in Europe as they introduced the generics portfolio in France. The company's subsidiary Aurigene Discovery Technologies launched a particular initiative to create oral immuno-oncology drugs in 2018. A crucial generic medicine for the treatment of opioid addiction was successfully introduced in the US. 2019 saw the entry of Dr. Reddy's Nutrition into the Indian nutrition market with the launch of Celevida, a ground-breaking product. For the cosmetic and aesthetic area, GLOWRIA, a 40-person, all-female medical representation team, was created. To provide a wide variety of COVID-19 medicines to India as the coronavirus pandemic spread around the globe, they got into significant relationships with international innovation businesses. In the US, they introduced the first generic Otic suspension product. In addition to some anti-allergy brands from the Glenmark portfolio in Russia, Ukraine, Kazakhstan, and Uzbekistan, they bought specific business divisions of Wockhardt in India. They joined the Science Based Targets program as the first pharmaceutical business in India.

Corporate Social Responsibility Information

The Company may carry out the following CSR-related projects or programs:

  • Fighting against hunger, poverty, and malnutrition, encouraging preventative care, cleanliness, and the provision of safe drinking water.
  • Projects to improve livelihoods and promote education, including special education and employment-enhancing vocation skills, particularly among children, women, older people, and people with disabilities.
  • Maintaining the quality of soil, air, and water while ensuring environmental sustainability, ecological balance, animal welfare, protection of flora and fauna, and agroforestry.
  • Education to promote Olympic, paralympic, and rural sports that are recognized nationwide.
  • Contribution to the prime minister's national relief fund, the PM CARES Fund, or any other fund established by the central government for the socio-economic development, relief, and welfare of the scheduled caste, tribes, other underprivileged classes, minorities, and women
  • Contributions to public-funded universities in the field of technology, national laboratories, and autonomous bodies engaged in conducting research in the fields of atomic energy, science, and technology
  • Contributions to incubators or research and development projects in the fields of science, technology, engineering, and medicine, funded by the Central Government or State Government or Public Sector Undertaking or any agency of the Central Government or State Government
  • Contributions to publicly funded research universities, national laboratories, and autonomous organizations conducting research in the fields of atomic energy, science, technology, biotechnology, pharmaceuticals, electronics, and information, as well as defense, agricultural, scientific, and industrial research, engineering, and medicine and listed in Schedule VII of the Act and its implementing regulations
  • projects for rural development.
  • Construction in slum areas.
  • Any other activities or subjects listed in Schedule VII of the Companies Act, 2013 (the Act) and the rules made thereunder, as amended from time to time, and circulars/notifications issued by statutory authorities.
  • Disaster management, including relief, rehabilitation, and reconstruction activities.
(+)
  • NSE Symbol
  • DRREDDY
  • BSE Symbol
  • 500124
  • ISIN
  • INE089A01031

Dr. Reddy's Laboratories FAQs

Dr. Reddy's Laboratories share price is ₹1,272 As on 05 November, 2024 | 19:08

The Market Cap of Dr. Reddy's Laboratories is ₹106150.4 Cr As on 05 November, 2024 | 19:08

The P/E ratio of Dr. Reddy's Laboratories is 19.1 As on 05 November, 2024 | 19:08

The PB ratio of Dr. Reddy's Laboratories is 3.8 As on 05 November, 2024 | 19:08

Dr Reddys Laboratories stock price CAGR for 10 Years stands at 12%, 5 Years at 8%, 3 Years at 20%, and 1 Year at -2%.

The ROE of Dr Reddys Laboratories is 11%.

Dr Reddy's Laboratories has an operating revenue of Rs. 20,442.10 Cr. on a trailing 12-month basis. Annual revenue growth of 7% is good, Pre-tax margin of 15% is great. As per analysts rating in the last 6 months, the recommendation is to HOLD Dr Reddys Laboratories.

Erez Israeli is the Chief Executive Officer (CEO) at Dr Reddy's Laboratories since 1 Aug 2019.

Profit before tax of Dr. Reddys Laboratories Ltd stock for the quarter ended March 2022 is Rs 567 crores.
 

Ans - You can easily buy the shares of Dr. Reddys Laboratories Ltd, by registering at 5Paisa and by setting up a Demat Account in your name.
 

Ans – Dr Reddys Laboratories Ltd shares have a 52-week high of Rs 5,614.60 and a 52-week low of Rs 3,654.
 

Ans – The Return on Equity on shares of Dr Reddys Laboratories Ltd is 11.8% for last year.
 

Ans – The face value of a share of Dr Reddys Laboratories Ltd. is INR 5 per share.

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form